Esperion Therapeutics Inc (NASDAQ:ESPR) price on Thursday, December 26, rose 0.87% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $2.32.
A look at the stock’s price movement, the close in the last trading session was $2.30, moving within a range at $2.16 and $2.34. The beta value (5-Year monthly) was 0.954. Turning to its 52-week performance, $3.94 and $1.58 were the 52-week high and 52-week low respectively. Overall, ESPR moved -9.73% over the past month.
Esperion Therapeutics Inc’s market cap currently stands at around $457.12 million, with investors looking forward to this quarter’s earnings report slated for in January.
Analysts have a consensus estimate of 62.14M for the company’s revenue for the quarter, with a low and high estimate of 47.34M and 84.6M respectively. The average forecast suggests up to a 92.68% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 327.16M, representing a 181.23% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ESPR is a 50% Buy. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 6 recommend ESPR as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ESPR’s current price about -15.18% and -4.14% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 45.30, while 7-day volatility ratio is 5.70% and 12.99% in the 30-day chart. Further, Esperion Therapeutics Inc (ESPR) has a beta value of 1.01, and an average true range (ATR) of 0.28. Analysts have given the company’s stock an average 52-week price target of $8, forecast between a low of $8 and high of $8. Looking at the price targets, the low is -244.83% off current price level while to achieve the yearly target high, price needs to move -244.83%. Nonetheless, investors will most likely welcome a -244.83% jump to $8 which is the analysts’ median price.
If we refocus on Esperion Therapeutics Inc (NASDAQ:ESPR), historical trading data shows that trading volumes averaged 9.56 over the past 10 days and 5.60 million over the past 3 months. The company’s latest data on shares outstanding shows there are 195.44 million shares.
The 0.99% of Esperion Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 65.84% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 30.49 million on 2024-11-29, giving us a short ratio of 5.7. The data shows that as of 2024-11-29 short interest in Esperion Therapeutics Inc (ESPR) stood at 1552.0 of shares outstanding, with shares short falling to 33.46 million registered in 2024-10-31. Current price change has pushed the stock -22.41% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ESPR stock continues to rise going into the next quarter.